KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Long-Term Investments (2019 - 2020)

Boston Scientific's Long-Term Investments history spans 7 years, with the latest figure at $643.0 million for Q3 2025.

  • For Q3 2025, Long-Term Investments rose 20.86% year-over-year to $643.0 million; the TTM value through Sep 2025 reached $643.0 million, up 20.86%, while the annual FY2024 figure was $555.0 million, 34.38% up from the prior year.
  • Long-Term Investments for Q3 2025 was $643.0 million at Boston Scientific, up from $626.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $655.0 million in Q1 2025 and bottomed at $389.0 million in Q3 2022.
  • The 5-year median for Long-Term Investments is $429.0 million (2024), against an average of $502.5 million.
  • The largest annual shift saw Long-Term Investments tumbled 55.12% in 2021 before it surged 52.68% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $412.0 million in 2021, then dropped by 1.21% to $407.0 million in 2022, then rose by 1.47% to $413.0 million in 2023, then surged by 34.38% to $555.0 million in 2024, then increased by 15.86% to $643.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Long-Term Investments are $643.0 million (Q3 2025), $626.0 million (Q2 2025), and $655.0 million (Q1 2025).